Table 5.

Overall SVR12 rate in Black vs non-Black patients from ION trials

Ethnicity	SVR rate (%)
Overall (n=1,951)	1,887/1,951 (97)
Black (n=308)	294/308 (95)
Non-Black (n=1,641)	1,591/1,640* (97)

Notes:

^*Excluding one patient with HCV-4 infection. Reproduced from Wilder JM, Jeffers LJ, Ravendhran N, et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology. Copyright © 2015 Wilder et al. HEPATOLOGY published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.43

Abbreviation: SVR12, sustained virologic response 12 weeks off therapy.